• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

端粒酶作为抗癌的一个有用靶点——以乳腺癌为例。

Telomerase as a useful target in cancer fighting-the breast cancer case.

作者信息

Holysz Hanna, Lipinska Natalia, Paszel-Jaworska Anna, Rubis Blazej

机构信息

Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, ul. Przybyszewskiego 49, 60-355, Poznan, Poland.

出版信息

Tumour Biol. 2013 Jun;34(3):1371-80. doi: 10.1007/s13277-013-0757-4. Epub 2013 Apr 5.

DOI:10.1007/s13277-013-0757-4
PMID:23558965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3661921/
Abstract

Telomerase was initially considered as a relevant factor distinguishing cancer from normal cells. During detailed studies, it appeared that its expression and activity is not only limited to cancer cells however, but in this particular cells, the telomerase is much more abundant. Thus, it has become a very promising target for an anticancer therapy. It was revealed in many studies that regulation of telomerase is a multifactorial process in mammalian cells, involving regulation of expression of telomerase subunits coding genes, post-translational protein-protein interactions, and protein phosphorylation. Numerous proto-oncogenes and tumor suppressor genes are engaged in this mechanism, and the complexity of telomerase control is studied in the context of tumor development as well as aging. Additionally, since numerous studies reveal a correlation between short telomeres and increased genome instability or cell mortality, the telomerase control appears to be one of the crucial factors to study in order to improve the cancer diagnostics and therapy or prevention. Interestingly, almost 100 % of adenocarcinoma, including breast cancer cells, expresses telomerase which makes it a good target for telomerase-related therapy. Additionally, telomerase is also supposed to be associated with drug resistance. Thus, targeting the enzyme might result in attenuation of this phenomenon. Moreover, since stem cells existence was reported, it must be considered whether targeting telomerase can bring some serious side effects and result in stem cells viability or their regenerative potential decrease. Thus, we review some molecular mechanisms engaged in therapy based on targeting telomerase in breast cancer cells.

摘要

端粒酶最初被认为是区分癌细胞与正常细胞的一个相关因素。在详细研究过程中发现,其表达和活性不仅限于癌细胞,然而在这些特定细胞中,端粒酶更为丰富。因此,它已成为抗癌治疗一个非常有前景的靶点。许多研究表明,在哺乳动物细胞中端粒酶的调控是一个多因素过程,涉及端粒酶亚基编码基因表达的调控、翻译后蛋白质 - 蛋白质相互作用以及蛋白质磷酸化。众多原癌基因和肿瘤抑制基因参与这一机制,并且在肿瘤发生发展以及衰老的背景下研究端粒酶控制的复杂性。此外,由于众多研究揭示了短端粒与基因组不稳定性增加或细胞死亡率之间的相关性,端粒酶控制似乎是为改善癌症诊断、治疗或预防而进行研究的关键因素之一。有趣的是,几乎100%的腺癌,包括乳腺癌细胞,都表达端粒酶,这使其成为端粒酶相关治疗的一个良好靶点。此外,端粒酶也被认为与耐药性有关。因此,靶向该酶可能会减弱这种现象。而且,自从报道了干细胞的存在后,必须考虑靶向端粒酶是否会带来一些严重的副作用并导致干细胞活力或其再生潜能下降。因此,我们综述了一些基于靶向乳腺癌细胞中端粒酶的治疗所涉及的分子机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/3661921/28cbc16b14dc/13277_2013_757_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/3661921/4c6383d6a953/13277_2013_757_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/3661921/28cbc16b14dc/13277_2013_757_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/3661921/4c6383d6a953/13277_2013_757_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/3661921/28cbc16b14dc/13277_2013_757_Fig2_HTML.jpg

相似文献

1
Telomerase as a useful target in cancer fighting-the breast cancer case.端粒酶作为抗癌的一个有用靶点——以乳腺癌为例。
Tumour Biol. 2013 Jun;34(3):1371-80. doi: 10.1007/s13277-013-0757-4. Epub 2013 Apr 5.
2
Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells.端粒酶抑制增强人乳腺癌细胞对抗癌药物治疗的反应。
Mol Cancer Ther. 2006 Jul;5(7):1669-75. doi: 10.1158/1535-7163.MCT-06-0033.
3
Human telomerase activity regulation.人类端粒酶活性的调控。
Mol Biol Rep. 2011 Jun;38(5):3339-49. doi: 10.1007/s11033-010-0439-x. Epub 2010 Nov 18.
4
Human telomerase expression regulation.人类端粒酶表达调控。
Biochem Cell Biol. 2011 Aug;89(4):359-76. doi: 10.1139/o11-037. Epub 2011 Jul 26.
5
Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.端粒酶模板拮抗剂GRN163L破坏乳腺癌的端粒维持、肿瘤生长和转移。
Clin Cancer Res. 2006 May 15;12(10):3184-92. doi: 10.1158/1078-0432.CCR-05-2760.
6
Studies of the molecular mechanisms in the regulation of telomerase activity.端粒酶活性调控的分子机制研究。
FASEB J. 1999 Dec;13(15):2091-104. doi: 10.1096/fasebj.13.15.2091.
7
Assessment of telomerase as drug target in breast cancer.端粒酶作为乳腺癌药物靶点的评估。
J Biosci. 2020;45.
8
Telomerase regulation: a key to inhibition? (Review).端粒酶调控:抑制的关键?(综述)。
Int J Oncol. 2013 Nov;43(5):1351-6. doi: 10.3892/ijo.2013.2104. Epub 2013 Sep 16.
9
Genetic inhibition of telomerase results in sensitization and recovery of breast tumor cells.端粒酶的遗传抑制导致乳腺癌细胞的敏化和恢复。
Mol Cancer Ther. 2009 May;8(5):1319-27. doi: 10.1158/1535-7163.MCT-08-0849. Epub 2009 May 5.
10
siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells.小干扰RNA对端粒酶的抑制增强了阿霉素对乳腺癌细胞的抗癌作用。
BMC Cancer. 2009 May 5;9:133. doi: 10.1186/1471-2407-9-133.

引用本文的文献

1
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.端粒、端粒酶与癌症:作用机制、生物标志物及治疗方法
Exp Hematol Oncol. 2025 Jan 27;14(1):8. doi: 10.1186/s40164-025-00597-9.
2
Telomerase inhibition in breast cancer and breast cancer stem cells: a brief review.端粒酶抑制在乳腺癌和乳腺癌干细胞中的作用:简要综述。
Med Oncol. 2024 Nov 25;42(1):14. doi: 10.1007/s12032-024-02562-8.
3
Obesity-Senescence-Breast Cancer: Clinical Presentation of a Common Unfortunate Cycle.肥胖-衰老-乳腺癌:一个常见不幸循环的临床表现。

本文引用的文献

1
1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498.1,25-二羟维生素 D3 通过 microRNA-498 抑制端粒酶表达和人癌细胞生长。
J Biol Chem. 2012 Nov 30;287(49):41297-309. doi: 10.1074/jbc.M112.407189. Epub 2012 Oct 10.
2
Is telomerase a viable target in cancer?端粒酶在癌症中是否是一个可行的靶点?
Mutat Res. 2012 Feb 1;730(1-2):90-7. doi: 10.1016/j.mrfmmm.2011.07.006. Epub 2011 Jul 23.
3
Human telomerase expression regulation.人类端粒酶表达调控。
Adv Exp Med Biol. 2024;1460:821-850. doi: 10.1007/978-3-031-63657-8_27.
4
Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer.激素对类固醇调节组织及癌症中端粒酶活性和人端粒酶逆转录酶(hTERT)表达的调控
Cancer Cell Int. 2022 Aug 16;22(1):258. doi: 10.1186/s12935-022-02678-9.
5
Modulating gene expression in breast cancer via DNA secondary structure and the CRISPR toolbox.通过DNA二级结构和CRISPR工具盒调控乳腺癌中的基因表达。
NAR Cancer. 2021 Dec 22;3(4):zcab048. doi: 10.1093/narcan/zcab048. eCollection 2021 Dec.
6
Transgenic Immortalization of Human Dermal Fibroblasts Mediated Through the MicroRNA/SIRT1 Pathway.通过 microRNA/SIRT1 通路介导的人真皮成纤维细胞的转基因永生化。
In Vivo. 2022 Jan-Feb;36(1):140-152. doi: 10.21873/invivo.12685.
7
Invasion and Metastasis as a Central Hallmark of Breast Cancer.侵袭和转移是乳腺癌的核心特征。
J Clin Med. 2021 Aug 8;10(16):3498. doi: 10.3390/jcm10163498.
8
Advances in the Antagonism of Epigallocatechin-3-gallate in the Treatment of Digestive Tract Tumors.没食子酸表没食子儿茶素在消化道肿瘤治疗中的拮抗作用的研究进展。
Molecules. 2019 May 3;24(9):1726. doi: 10.3390/molecules24091726.
9
Interleukin 8 is a biomarker of telomerase inhibition in cancer cells.白细胞介素 8 是癌细胞中端粒酶抑制的生物标志物。
BMC Cancer. 2018 Jul 9;18(1):730. doi: 10.1186/s12885-018-4633-x.
10
Telomerase and drug resistance in cancer.端粒酶与癌症中的耐药性
Cell Mol Life Sci. 2017 Nov;74(22):4121-4132. doi: 10.1007/s00018-017-2573-2. Epub 2017 Jun 16.
Biochem Cell Biol. 2011 Aug;89(4):359-76. doi: 10.1139/o11-037. Epub 2011 Jul 26.
4
Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells.色氨酸-3-羧基醇下调端粒酶基因表达需要抑制雌激素受体-α和 Sp1 转录因子在 hTERT 启动子内的相互作用,并介导人乳腺癌细胞的 G1 细胞周期停滞。
Carcinogenesis. 2011 Sep;32(9):1315-23. doi: 10.1093/carcin/bgr116. Epub 2011 Jun 21.
5
Histone deacetylase inhibition as an anticancer telomerase-targeting strategy.组蛋白去乙酰化酶抑制作为一种针对端粒酶的抗癌策略。
Int J Cancer. 2011 Dec 15;129(12):2765-74. doi: 10.1002/ijc.26241. Epub 2011 Aug 8.
6
hTERT regulation by NF-κB and c-myc in irradiated HER2-positive breast cancer cells.NF-κB 和 c-myc 对辐射诱导的 HER2 阳性乳腺癌细胞中端粒酶逆转录酶的调控。
Int J Radiat Biol. 2011 Jun;87(6):609-21. doi: 10.3109/09553002.2011.572112.
7
High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis.高迁移率族蛋白 A2 调节端粒酶逆转录酶转录促进肿瘤发生。
Mol Cell Biol. 2011 Jul;31(13):2605-17. doi: 10.1128/MCB.05447-11. Epub 2011 May 2.
8
Inhibition of telomerase activity by HDV ribozyme in cancers.HDV 核酶抑制肿瘤中端粒酶活性。
J Exp Clin Cancer Res. 2011 Jan 6;30(1):1. doi: 10.1186/1756-9966-30-1.
9
Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells.促红细胞生成素通过转录和转录后调控在人红白血病 JAS-REN-A 细胞中激活端粒酶。
Leuk Res. 2011 Mar;35(3):416-8. doi: 10.1016/j.leukres.2010.11.002. Epub 2010 Dec 15.
10
Telomeres in cancer and ageing.端粒与癌症和衰老。
Philos Trans R Soc Lond B Biol Sci. 2011 Jan 12;366(1561):76-84. doi: 10.1098/rstb.2010.0291.